Ebola Update 9/8/14

September 8th, 2014

Situation Update

The tally of Ebola cases in West Africa climbed to 3,685 as of Aug 31, with 1,841 deaths, representing a 20% jump over a 5-day period, the World Health Organization (WHO) reported today.

The total case count is 3685 with 1,841 deaths. The numbers include cases in Liberia, Guinea, and Sierra Leone.  Liberia, the hardest-hit country, has had 1,698 cases and 871 deaths—increases of 320 and 177 since the previous update.

Cases have occurred in the following countries:

Country information

  • Guinea
  • Liberia
  • Nigeria
  • Senegal
  • Sierra Leone

http://www.cidrap.umn.edu/news-perspective/2014/09/west-africas-ebola-count-soars-higher

For the latest information regarding case definition and diagnosis and testing please visit:

http://www.cdc.gov/vhf/ebola/hcp/index.html

For the latest information about infection control:  http://www.cdc.gov/vhf/ebola/hcp/infection-prevention-and-control-recommendations.html

For the latest information regarding monitoring exposed persons: http://www.cdc.gov/vhf/ebola/hcp/monitoring-and-movement-of-persons-with-exposure.html

 Risk Exposure per CDC:

  • All cases of human illness or death have occurred in Africa (with the exception of several laboratory contamination cases: one in England and two in Russia)
    • No cases have been reported in the United States
    • In 2014, two U.S. healthcare workers who were infected with Ebola virus in Liberia were transported to a hospital in the United States.
    • Those at highest risk include healthcare workers.

Medical Interventions under Investigation

A WHO background document lists seven experimental therapies and two vaccines under review. The therapies include ZMapp, made by Mapp Biopharmaceutical, which is a mixture of three monoclonal antibodies that are produced in tobacco plants. The drug has already been used in several patients and is thought to have contributed to the recovery of two American medical missionaries who contracted Ebola in Liberia. Other therapies listed include convalescent plasma, hyperimmune globulin prepared from the plasma of immunized animals or previously infected humans, interferons, and products made by Tekmira, Sarepta, Toyama Chemical/Fuji Film, and BioCryst. There are also two recombinant vaccines that have yielded promising results in animal experiments.

Questions call Deb McMahan, MD